Arca Biopharma Inc  

(Public, NASDAQ:ABIO)   Watch this stock  
Find more results for ABIO
+0.10 (7.41%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.35 - 1.45
52 week 1.05 - 3.00
Open 1.35
Vol / Avg. 45,166.00/116,215.00
Mkt cap 17.97M
P/E     -
Div/yield     -
EPS -1.92
Shares 11.75M
Beta 1.86
Inst. own 48%
Nov 9, 2017
Q3 2017 ARCA Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -103.93% -51.23%
Return on average equity -122.21% -54.57%
Employees 20 -
CDP Score - -


11080 Circle Point Rd Ste 140
WESTMINSTER, CO 80020-2769
United States - Map
+1-720-9402200 (Phone)
+1-720-2089261 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Officers and directors

Robert E. Conway Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Michael R. Bristow M.D., Ph.D. President, Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Thomas A. Keuer Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Christopher David Ozeroff Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Brian L. Selby CPA Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Linda S. Grais M.D. Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Anders D. Hove M.D. Director
Age: 50
Bio & Compensation  - Reuters
Daniel J. Mitchell Director
Age: 58
Bio & Compensation  - Reuters
Raymond L. Woosley M.D., Ph.D. Director
Age: 72
Bio & Compensation  - Reuters